FDA Approves First Generic of Once-Daily GLP-1 Injection to …
Dec 23, 2024 · Español. Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) receptor ...
GLP-1 drugs protect brain health by improving neurovascular …
Oct 7, 2024 · In a recent review published in the journal Cell Metabolism, a group of authors explored how Glucagon-Like Peptide-1 receptor (GLP-1R) agonism shapes the neurovascular unit (NVU), potentially...
Science’s Breakthrough of the Year: GLP-1 agonists can blunt …
Dec 15, 2023 · Science has named the development of glucagon like peptide-1 (GLP-1) agonists and this year's discovery that these drugs can blunt obesity-associated health problems as its 2023...
New hope for binge eating and bulimia: GLP-1 drugs could be the …
Mar 4, 2024 · Glucagon-like peptide-1 (GLP-1) is a hormone and neuropeptide produced in the intestine and brain. This hormone inhibits appetite, reduces food intake, reduces body weight, and stimulates...
Glucagon-like peptide-1 receptor: mechanisms and advances in …
Sep 18, 2024 · We introduce recent studies that demonstrate the remarkable performance of GLP-1RAs in slowing the progression of neurodegenerative diseases, reducing inflammation, and enhancing cardiovascular...
Harvard Medical School Researcher Wins 2024 Lasker Award for …
Sep 19, 2024 · Harvard Medical School researcher Joel Habener has won the 2024 Lasker~DeBakey Clinical Medical Research Award for his discovery of glucagon-like peptide-1 (GLP-1), a molecule that has become the basis for therapies which have transformed the treatment of obesity.
GLP-1 agonists: US sees 700% increase over four years in ... - The BMJ
Jul 23, 2024 · The number of patients without diabetes but with overweight or obesity who started glucagon like peptide-1 receptor agonist (GLP-1RA) treatment in the US has risen from around 21 000 in 2019 to over 174 000 in 2023—a rise of more than 700%—a study has found. 1
Obesity and Glucagon-Like Peptide-1 Receptor Agonists
Dec 18, 2024 · After many years of remarkable advances in basic science, novel therapeutic interventions have emerged, offering the promise of an effective treatment for obesity. Should the world embrace this novel pharmacological solution as the answer to the obesity pandemic?
Research shows GLP-1 receptor agonist drugs are effective but …
Jun 4, 2024 · They all belong to a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1RAs), which mimic a hormone (GLP-1) in the body that helps control insulin and blood glucose...
Special Report: Potential Strategies for Addressing GLP-1 and Dual …
Apr 7, 2023 · Unexpected drug shortages of the long-acting glucagon-like peptide 1 (GLP-1) receptor agonists dulaglutide and semaglutide and the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide emerged in late 2022 and have persisted through the first quarter of 2023 (1).